组合型人工肝的研究进展  

Research advances in combined artificial liver

作　　者：黄玥 彭虹[1] 罗新华[1] HUANG Yue;PENG Hong;LUO Xinhua(Department of Infectious Diseases,Guizhou Provincial People’s Hospital,Guizhou 550000,China)

机构地区：[1]贵州省人民医院感染科,贵阳550000

出　　处：《临床肝胆病杂志》2024年第2期233-238,共6页Journal of Clinical Hepatology

基　　金：贵州省科学技术基金(黔科合基础-ZK[2021]重点013)。

摘　　要：目前体外人工肝支持系统在各种原因导致的肝衰竭、肝移植前后无功能时期、严重胆汁性淤积等疾病中取得良好治疗效果。其中非生物型人工肝(NBAL)通过各种模式互补组合广泛应用于临床,主要以改善机体凝血因子和白蛋白等物质的血浆置换模式联合其余增强清除体内有毒物质谱的模式。以肝细胞的合成、转化功能为设计理念的生物型人工肝(BAL)近年也取得飞速发展。肝衰竭患者先经NBAL解毒后,再予以BAL合成、转化体内活性物质,能更接近人体肝脏正常生理功能。根据患者病情个体化组合NBAL模式,再结合疗效稳定的BAL是未来重症肝病患者体外支持治疗方向。At present,in vitro artificial liver support system has achieved a good therapeutic effect in the diseases such as liver failure due to various causes,non-function state before and after liver transplantation,and severe cholestasis.Non-bioartificial liver(NBAL)is widely used in clinical practice through various combinations of modes,mainly the plasma exchange mode for improving coagulation factors and albumin combined with other modes for enhancing the elimination of toxic substances in the body.Bioartificial liver(BAL),based on the design concept of the synthesis and transformation of hepatocytes,has achieved rapid development in recent years.Patients with liver failure can almost obtain the normal physiological function of human liver after NBAL detoxification and BAL synthesis and transformation of active substances in the body.NBAL mode combined with BAL with a stable therapeutic effect according to the conditions of the patient is the direction of in vitro support treatment for patients with severe liver disease in the future.

关 键 词：组合型非生物人工肝 组合型生物人工肝 治疗学 

分 类 号：R318.14[医药卫生—生物医学工程]